BostonGene has received both Research & Development and Innovation awards in the 2025 Clinical Trials Arena Excellence Awards, recognizing its AI-powered, clinically validated solutions that enable pharmaceutical companies to de-risk oncology pipelines, accelerate development timelines, and improve the probability of clinical and regulatory success.
The Clinical Trials Arena Excellence Awards recognize organizations delivering measurable impact across the pharmaceutical clinical development lifecycle, from early discovery through late-stage trials and regulatory execution. Powered by GlobalData’s business intelligence, the Awards highlight companies that translate advanced science into tangible improvements in trial performance, capital efficiency, and patient outcomes.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BostonGene won the Innovation award in the Multiomic AI Platforms category for its advanced platform, which integrates complex biological and clinical data to inform high-impact clinical development decisions. By combining multiomic data with AI-driven tumor and drug modeling, the platform improves patient selection, optimizes trial design, and enables earlier detection of efficacy, resistance, and safety signals. The company also received the Research and Development award in the AI-Driven Biomarker Discovery category for its AI-powered solutions that accelerate discovery and validation of novel biomarkers leading to improved therapy response prediction.
De-risking Oncology Drug Development through Integrating Multiomic AI
BostonGene’s Innovation award reflects its ability to synthesize genomics, transcriptomics, immune system profiling, spatial imaging, and clinical data within a single AI-powered platform purpose-built to support adaptive trial design and earlier, higher-confidence development decisions.
This integrated approach provides a multidimensional understanding of tumor and immune biology, enabling pharmaceutical partners to identify mechanisms of response and resistance earlier, reduce uncertainty, and optimize clinical strategy across development stages.
Unlike traditional approaches reliant on static tissue biopsies, BostonGene’s blood-based analytics enable real-time, longitudinal monitoring of tumor and immune dynamics throughout treatment. This continuous monitoring allows sponsors to evaluate treatment response, detect resistance and toxicity signals earlier, and implement adaptive trial strategies that reduce cost, shorten timelines, and improve decision quality.
The platform’s cell-free RNA (cfRNA) analysis reveals dynamic tumor signaling pathways, tumor microenvironment subtypes, and metastatic indicators that evolve rapidly during treatment and directly influence therapeutic outcomes. In hematologic malignancies, BostonGene’s cfRNA-based liquid biopsy delivers high-resolution insight into disease progression and therapy response within days of treatment initiation, enabling faster assessment of drug activity.
A complementary analytical framework supports circulating tumor DNA (ctDNA)-based minimal residual disease detection, enabling earlier and more precise identification of recurrence and informing post-treatment clinical strategy.
By integrating these multiomic data streams, BostonGene delivers actionable molecular intelligence that supports adaptive trial designs, improves operational efficiency, and increases overall probability of trial success. For pharmaceutical sponsors, this translates into more efficient patient selection, optimized enrollment, improved safety monitoring, and higher likelihood of achieving meaningful clinical endpoints.
The platform’s scalability enables deployment across global trial networks, supporting enterprise-wide adoption across multiple programs and indications. BostonGene’s innovations are validated through high-impact publications and presentations at leading scientific conferences, reinforcing scientific rigor while demonstrating translational relevance for active clinical programs.
AI-driven Biomarker Strategies that Increase Oncology Trial Success
BostonGene’s Research & Development award reflects its leadership in AI-driven biomarker discovery and clinical validation, with solutions embedded directly into pharmaceutical drug development pipelines to support translational research and late-stage decision-making.
Traditional biomarker strategies often rely on static, single-dimensional signals that fail to capture tumor and immune dynamics, contributing to inefficient patient stratification, increased attrition, and late-stage trial failures. BostonGene addresses these limitations through AI models trained on billions of data points spanning whole exome sequencing, whole transcriptome sequencing, liquid biopsy, immune profiling, and clinical outcomes.
A notable example is BostonGene’s next-generation immune profiling platform, developed from flow cytometry and RNA-seq data across more than 18,000 blood samples. This platform identifies reproducible immune states that predict response to immunotherapy across multiple cancer types and outperform conventional biomarkers such as PD-L1 expression and tumor mutational burden.
Beyond response prediction, BostonGene’s AI-powered solutions identify patients at elevated risk for immune-related adverse events prior to treatment, enabling proactive safety management, improved benefit-risk profiles, and more confident clinical decision-making.
BostonGene’s biomarker and modeling capabilities have been applied across immuno-oncology and targeted therapies, supporting patient stratification, response prediction, and resistance characterization across multiple tumor types. These capabilities strengthen regulatory submissions, support label expansion strategies, and improve overall portfolio efficiency.
Company Profile
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and artificial intelligence. Built and validated through an extensive real-world clinical testing network, BostonGene’s Foundation Model of cancer and the immune system integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners to design and de-risk trials, identify novel targets, and optimize therapeutic response prediction across all stages of development while simultaneously improving patient care through clinically integrated innovation. For more information, visit www.BostonGene.com.
Links
Website: https://bostongene.com/
